We have located links that may give you full text access.
JOURNAL ARTICLE
META-ANALYSIS
REVIEW
SARC-F for Screening of Sarcopenia Among Older Adults: A Meta-analysis of Screening Test Accuracy.
OBJECTIVE: To examine the screening ability of SARC-F for older adults using a meta-analysis.
DESIGN: Meta-analysis.
SETTING AND PARTICIPANTS: The literature review was conducted using MEDLINE, Cochrane Database of Systematic Reviews, and ClinicalTrials.gov. Articles written on and after 1960 that included data regarding the sensitivity and specificity of SARC-F's diagnostic criteria for sarcopenia in older adults were searched.
MEASURES: The bivariate random effects model was used to calculate the summary estimates of sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR). The summary receiver operating characteristic curve was used to summarize the overall test performance.
RESULTS: Seven studies involving a total of 12,800 subjects met the eligibility criteria of our study. The pooled results of sensitivity, specificity, PLR, NLR, and DOR with the European Working Group on Sarcopenia in Older People as the reference standard were 0.21 [95% confidence interval (CI), 0.13-0.31], 0.90 (95% CI, 0.83-0.94), 2.16 (95% CI, 1.51-3.09), 0.87 (95% CI, 0.80-0.95), and 2.47 (95% CI, 1.64-3.74), respectively. Overall, we achieved similar pooled results of sensitivity and specificity for studies using the International Working Group on Sarcopenia and Asian Working Group for Sarcopenia as the reference standards. Because few studies used the Foundation National Institute of Health reference standards, a meta-analysis was not performed.
CONCLUSIONS/IMPLICATIONS: Although the screening sensitivity performance of SARC-F was poor, its specificity was high; thus, it is an effective tool for selecting subjects who should undergo further testing for confirming a diagnosis of sarcopenia.
DESIGN: Meta-analysis.
SETTING AND PARTICIPANTS: The literature review was conducted using MEDLINE, Cochrane Database of Systematic Reviews, and ClinicalTrials.gov. Articles written on and after 1960 that included data regarding the sensitivity and specificity of SARC-F's diagnostic criteria for sarcopenia in older adults were searched.
MEASURES: The bivariate random effects model was used to calculate the summary estimates of sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR). The summary receiver operating characteristic curve was used to summarize the overall test performance.
RESULTS: Seven studies involving a total of 12,800 subjects met the eligibility criteria of our study. The pooled results of sensitivity, specificity, PLR, NLR, and DOR with the European Working Group on Sarcopenia in Older People as the reference standard were 0.21 [95% confidence interval (CI), 0.13-0.31], 0.90 (95% CI, 0.83-0.94), 2.16 (95% CI, 1.51-3.09), 0.87 (95% CI, 0.80-0.95), and 2.47 (95% CI, 1.64-3.74), respectively. Overall, we achieved similar pooled results of sensitivity and specificity for studies using the International Working Group on Sarcopenia and Asian Working Group for Sarcopenia as the reference standards. Because few studies used the Foundation National Institute of Health reference standards, a meta-analysis was not performed.
CONCLUSIONS/IMPLICATIONS: Although the screening sensitivity performance of SARC-F was poor, its specificity was high; thus, it is an effective tool for selecting subjects who should undergo further testing for confirming a diagnosis of sarcopenia.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app